UK Markets close in 7 hrs 1 min
  • FTSE 100

    7,408.21
    +105.47 (+1.44%)
     
  • FTSE 250

    19,972.06
    +283.04 (+1.44%)
     
  • AIM

    958.72
    +11.55 (+1.22%)
     
  • GBP/EUR

    1.1802
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2471
    -0.0003 (-0.0274%)
     
  • BTC-GBP

    24,273.54
    +778.10 (+3.31%)
     
  • CMC Crypto 200

    674.55
    +22.31 (+3.42%)
     
  • S&P 500

    3,900.79
    -22.89 (-0.58%)
     
  • DOW

    31,253.13
    -236.94 (-0.75%)
     
  • CRUDE OIL

    111.65
    -0.56 (-0.50%)
     
  • GOLD FUTURES

    1,841.80
    +0.60 (+0.03%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    14,060.98
    +178.68 (+1.29%)
     
  • CAC 40

    6,324.21
    +51.50 (+0.82%)
     

Global Cell-Based Assay market is projected to reach at a market value of US$ 35,033.9 Million by 2030: Visiongain Research Inc

·7-min read
Visiongain Ltd
Visiongain Ltd

Visiongain has published a new study on the global Cell-based Assay Market Report, Forecast 2020-2030. Forecasts by Product (Consumables, Instruments, and Software & Services) By Technology (Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening) By Application (Drug Discovery, Basic Research, ADME Studies, Predictive Technology) By End-User (Pharma & Biotech Companies, Academic Institutes, CROs). PLUS, Profiles of Leading Cell-based Assay Companies and Regional and Leading National Market Analysis. PLUS, COVID-19 Recovery Scenarios

The Global cell-based assay market was valued at US$ 15,927.5 million in 2020 and is projected to reach at a market value of US$ 35,033.9 million by 2030. The increase is due to a growing incidence of chronic diseases, increasing R&D investment for drug discovery research and a growing adoption of High-Throughput Screening methodology’.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/cell-based-assays-market/#download_sampe_div

COVID-19 on the Cell-based Assays market?

According to ClinicalTrials.gov, currently, over 2,500 COVID-19 interventional clinical trials have been initiated, with around 600 of these in Phase III. A number of these COVID-19 drug targets have been investigated by researchers in cell-based assay systems to discover small molecule modulators that can be used to treat the disease. The outbreak of novel COVID-19 is anticipated to create lucrative opportunities in the cell-based assays market due to rising R&D investment for COVID-19 vaccine development and another advanced drug development. During 2021, it is expected that several COVID-19 small molecule clinical trials will be completed, with the expectation that a small number of drugs will gain approval for clinical use.

Several manufacturers of vaccines around the world have expanded their testing ability to find an effective coronavirus vaccine. Higher vaccine demand is expected to place pressure on manufacturers and healthcare professionals to supply the vaccine. The increasing numbers of funding to encourage immunisation and product development by government and private organisations are the key drivers of the demand for cell-based assay.

What are the key market drivers?

Cell-based assays, because of their peculiar advantages of predictability, possibility of automation, multiplexing, and miniaturization, seem the most appealing tool for the high demands of the early stages of the drug-discovery process.

Cell-based assays have been a key component in streamlining the drug development process, helping drugs be brought to the market in a quick and efficient manner, and their technological evolution is not slowing down. While cytotoxicity remains a primary effect that drug developers use cell-based assays to quantify, biological activity, biochemical mechanisms and off-target interactions are also being investigated using this technique. Due to their amenability to miniaturization and multiplexing, cell cultures are being used for high-throughput screening (HTS) to test many compounds under different conditions in parallel. Today, cell-based assays are used in more than half of all high-throughput drug screenings for target validation and ADMET (absorption, distribution, metabolism, elimination and toxicity) in the early stage of drug discovery. Additionally, cell-based assays are the preferred tool for screening potential drug compounds and toxicity screening, driving the demand by drug development companies. The demand for cell-based assays will expand further due to increased allocation of resources towards drug discovery by companies, the presence of many proteins which still have unknown functions, and the rising demand for biological drugs.

What are the market opportunities?

Cell-based assays is gaining increasing acceptance in assessing potency of drugs. Potency of biotherapeutics, often determined by cell-based assays, is one of the most important critical quality attributes. Potency must be monitored throughout the entire drug development cycle as it measures drug activity and provides a direct link to clinical efficacy. An ideal potency assay should represent a drug’s mechanism of action (MOA), as well as be specific and sensitive enough to detect changes and degradations of the product. Thus, the adoption of cell-based potency assays is likely to increase over the forecast period.

Label-free cell-based assay technology is opening new doors for drug discovery applications. In recent years, the technology has emerged as an innovative tool in the field of biochemical binding assays and cellular research. Due to the benefits of its non-invasiveness, integrated cellular response and excellent sensitivity in biochemical binding assays and endogenous cellular systems, the technology is gaining popularity.

Get Detailed TOC @ https://www.visiongain.com/report/cell-based-assays-market/#download_sampe_div

Competitive Landscape

Cell based assay market is a highly competitive market with several global and local players. Some of the leading players in this market include DiscoverX Corporation (Eurofins DiscoverX); Thermo Fisher Scientific, Inc.; Cell Assay Innovations, Inc.; InSphero AG; QGel SA; Becton, Dickinson and Company; Promega Corp.; BioVision, Inc.; Marin Biologic Laboratories; Molecular Devices, LLC.; Porsolt; CYTOO SA; Pharmaceutical Product Development (PPD); ProQinase GmbH; Charles River Laboratories International, Inc.; BioAgilytix Labs; SGS Group; Perkin Elmer Inc.; General Electric Company; F. Hoffmann-La Roche AG; Merck KGaA.

The major strategies acquired by the leading players are collaborations, M&A, high investment in R&D, new product launches, and geographical expansion. These strategies help the companies to reinforce their existing product portfolio and regional reach. For instance, in February 2020, Eurofins DiscoverX, the products company of Eurofins Discovery announced their partnership with VelaLabs of Vienna, Austria, in which Eurofins DiscoverX is granting the status of Bioassay Certified CRO to VelaLabs as a certified provider of PathHunter assay services. VelaLabs has successfully demonstrated their capability to expeditiously implement client-sponsored GLP validation programs that use the PathHunter platform. PathHunter bioassays are being adopted by top global pharma and biotech companies as mechanism of action (MOA)-reflective functional assays for potency lot release studies. The simplicity of the platform, coupled with a broad menu, makes it attractive to the clients to drive their drug molecules for filings by using the assays.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Cell based assay market and leading companies. You will find data, trends and predictions.

Find more Visiongain research reports on Pharma Drug Production click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

About Visiongain

Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter

-

SOURCE Visiongain Limited.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting